Welcome to Markets Desk, here's what's moving the needle this hour.
Eli Lilly is drawing fresh attention, and not just for its blockbuster GLP-one franchise. The company is quietly deploying three point eight billion dollars into vaccine development, a bet that many investors are overlooking entirely as they chase the weight-loss drug narrative. That diversification could matter enormously to long-term holders.
Speaking of GLP-ones, the competitive landscape is heating up fast. A new wave of experimental weight-loss therapies is in development, targeting the very side effects that plague Zepbound and Wegovy users, namely nausea and the daily pill burden. Researchers are exploring next-generation mechanisms that could challenge Lilly and Novo Nordisk's current dominance sooner than the market is pricing in.
Meanwhile, Amazon continues to make a compelling case for itself in the cloud. AWS revenue growth accelerated for a third consecutive quarter, a streak that signals sustained enterprise demand rather than a one-time pop. With AI workloads driving infrastructure spending, analysts are revisiting price targets and asking whether the stock's current valuation still leaves room on the table.
That's the tape. Markets Desk, signing off the floor.
